Date: {{$ActivityAssignDate}}

Dear Dr. {{$doctorName}},

Subject:Assessment of drug utilization pattern of lipid lowering agents including statin and combinations of statin in patients with T2DM (BEAT Ⅱ)

In India, ICMR INDIAB study estimated that in India 101 million people had diabetes, and the number with prediabetes was 136 million. It is well-established that dyslipidemia is a major risk factor for macrovascular complications in patients with type-2 diabetes mellitus (T2DM). The prevalence of dyslipidemia [defined according to National Cholesterol Education Programme (NCEP) guidelines] in Indians is very high with 79% of subjects having at least one lipid abnormality, with decreased high density lipoprotein cholesterol (HDL-C) levels in 72.3% subjects, hypertriglyceridemia in 29.5% subjects and elevated low density lipoprotein cholesterol (LDL-C) levels in 11.8% of subjects. Moreover, if these patients when optimally treated with lipid lowering therapy has shown to significantly reduce CVD events and cardiovascular risks. Although diabetes and dyslipidemia commonly coexist in India, there is a lack of evidence on whether dyslipidemia is adequately managed or not, in alignment with LAI 2023.

We at Sun pharmaceutical have planned a retrospective, cross-sectional multicenter study to evaluate drug utilization pattern of lipid lowering agents including statin and combinations of statin in patients with T2DM in India.

We invite you to participate in this study. On acceptance, you will need to capture the relevant data as mentioned in the standard Data Collection Form (DCF) provided, from the patient’s medical records (case papers and investigational reports – hereafter referred as source documents).

We would recommend you to capture data as outlined in the protocol and patients’ relevant laboratory investigations are available for the preceding 3 months.

We wish to inform you that the DCF will capture all data in de-identified form and any identifiable parameters which may potentially disclose the identity of the patient such as name or address will not be captured so as to ensure patient’s confidentiality. We would encourage you to carefully capture all available information to the fullest as recommended in the DCF.

If you agree to participate in the said study, we would request you to sign and return the enclosed reply along with your visiting card for accuracy of records.